Biognosys Unveils Enhanced Plasma Proteomics Services for Deep and High-Throughput Biomarker Discovery

ZURICH, Switzerland and NEWTON, Massachusetts, March 20, 2024. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the release of enhanced plasma proteomics workflows for its TrueDiscovery® unbiased discovery proteomics research services platform. The new workflows leverage an innovative plasma enrichment method, delivering deep proteome coverage with...

read more

InSphero and PharmaNest Unveil a Promising Tool for MASH Drug Discovery in a Breakthrough Study

Zürich, March 13, 2024 InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery. The study, in collaboration with PharmaNest, fills an existing gap, by developing and demonstrating a novel method for phenotypic quantification of fibrosis, using the...

read more

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

Schlieren (Zurich), Switzerland, March 13, 2024 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next-generation bone graft technologies, today announced financial results for full year 2023 along with continued significant growth. Direct sales of MagnetOs rose 163% to CHF 31.7 million in 2023 from CHF 12.1 million in 2022. Total...

read more